Percent Of Disability

[BIGJOE]

HI, I HAVE A 10%DISABILITY FOR SKIN DERMATITIS AND HAVE BEEN TURNED DOWN TWO TIMES FOR A INCREASE.THEY SAY I MUST HAVE BETWEEN 20 AND 40% OF MY BODY WITH IT.IF I HAVE IT ON MY

(HANDS,FEET,HEAD,GROIN,BACK) WHAT PERCENT OF MY BODY WOULD THIS BE?I HAVE RESEARCHED FOR HOURS WITH NO LUCK.PLEASE HELP. THANKS JOE

[carlie]

38 CFR -- Schedule of rating the skin

http://ecfr.gpoaccess.gov/cgi/t/text/text-....106.64&idno=38

Hope this helps,

carlie

[BIGJOE]

HI, I HAVE A 10%DISABILITY FOR SKIN DERMATITIS AND HAVE BEEN TURNED DOWN TWO TIMES FOR A INCREASE.THEY SAY I MUST HAVE BETWEEN 20 AND 40% OF MY BODY WITH IT.IF I HAVE IT ON MY

(HANDS,FEET,HEAD,GROIN,BACK) WHAT PERCENT OF MY BODY WOULD THIS BE?I HAVE RESEARCHED FOR HOURS WITH NO LUCK.PLEASE HELP. THANKS JOE

thanks carlie,but i still cant find a chart giving the percentages of the body.

[vaf]

A visit to a private practice dermatologist appears to be in order. The doc can probably answer your question, in writing, which is what you'll need anyway as a professional evaluation/opinion to support your request for increase. If you can do this, it would help for you to bring a hard copy of the section Carlie provided the link for in 38 CFR, and ask the doc to determine within those standards where your condition lies.

[BIGJOE]

A visit to a private practice dermatologist appears to be in order. The doc can probably answer your question, in writing, which is what you'll need anyway as a professional evaluation/opinion to support your request for increase. If you can do this, it would help for you to bring a hard copy of the section Carlie provided the link for in 38 CFR, and ask the doc to determine within those standards where your condition lies.

THANKS VICKI, BUT I ALREADY HAVE AN UP TODATE C&P EXAM REPORT WHICH INCLUDES PROVE FOR MY INCREASE I THINK?WHAT IM LOOKING FOR IS A CHART FOR THE PERCENTAGES OF THE BODY.WHEN I GO IN FRONT OF THE COURT OF APPEALS I WANT TO PROVE TO THEM I AM 20% OR MORE.IT MUST BE A SECRET AS TO HOW THEY INTERPET THE PERCENT OF THE BODY WHICH IS SUFFERED,BECAUSE I READ EVERYTHING POSSIBLE IN VA FILES.IF ANYBODY CAN HELP ME ON THIS I WOULD BE GRATEFUL JOE.

[carlie]

Big Joe,

Here's another link for your research.

http://www.afip.org/sitemap.html

Good luck,

carlie

[Alex]

Joe --

Following are diagnosic criteria for ratin skin condiions:

800 Disfigurement of the head, face, or neck:

With visible or palpable tissue loss and either gross 80

distortion or asymmetry of three or more features or

paired sets of features (nose, chin, forehead, eyes

(including eyelids), ears (auricles), cheeks, lips), or;

with six or more characteristics of disfigurement

With visible or palpable tissue loss and either gross 50

distortion or asymmetry of two features or paired sets of

features (nose, chin, forehead, eyes (including eyelids),

ears (auricles), cheeks, lips), or; with four or five

characteristics of disfigurement

With visible or palpable tissue loss and either gross 30

distortion or asymmetry of one feature or paired set of

features (nose, chin, forehead, eyes (including eyelids),

ears (auricles), cheeks, lips), or; with two or three

characteristics of disfigurement

With one characteristic of disfigurement 10

Note (1):The 8 characteristics of disfigurement, for

purposes of evaluation under § 4.118, are:

Scar 5 or more inches (13 or more cm.) in length.

Scar at least one-quarter inch (0.6 cm.) wide at widest

part.

Surface contour of scar elevated or depressed on

palpation.

Scar adherent to underlying tissue.

Skin hypo-or hyper-pigmented in an area exceeding six

square inches (39 sq. cm.).

Skin texture abnormal (irregular, atrophic, shiny, scaly,

etc.) in an area exceeding six square inches (39 sq.

cm.).

Underlying soft tissue missing in an area exceeding six

square inches (39 sq. cm.).

Skin indurated and inflexible in an area exceeding six

square inches (39 sq. cm.).

Note (2): Rate tissue loss of the auricle under DC 6207

(loss of auricle) and anatomical loss of the eye under DC

6061 (anatomical loss of both eyes) or DC 6063

(anatomical loss of one eye), as appropriate.

Note (3): Take into consideration unretouched color

photographs when evaluating under these criteria.

7801 Scars, other than head, face, or neck, that are deep

or that cause limited motion:

Area or areas exceeding 144 square inches (929 sq.cm.) 40

Area or areas exceeding 72 square inches (465 sq. cm.) 30

Area or areas exceeding 12 square inches (77 sq. cm.) 20

Area or areas exceeding 6 square inches (39 sq. cm.) 10

Note (1): Scars in widely separated areas, as on two or

more extremities or on anterior and posterior surfaces of

extremities or trunk, will be separately rated and

combined in accordance with § 4.25 of this part.

Note (2): A deep scar is one associated with underlying

soft tissue damage.

7802 Scars, other than head, face, or neck, that are

superficial and that do not cause limited motion:

Area or areas of 144 square inches (929 sq. cm.) or 10

greater

Note (1): Scars in widely separated areas, as on two or

more extremities or on anterior and posterior surfaces of

extremities or trunk, will be separately rated and

combined in accordance with § 4.25 of this part.

Note (2): A superficial scar is one not associated with

underlying soft tissue damage.

7803 Scars, superficial, unstable 10

Note (1): An unstable scar is one where, for any reason,

there is frequent loss of covering of skin over the scar.

Note (2): A superficial scar is one not associated with

underlying soft tissue damage.

7804 Scars, superficial, painful on examination 10

Note (1): A superficial scar is one not associated with

underlying soft tissue damage.

Note (2): In this case, a 10-percent evaluation will be

assigned for a scar on the tip of a finger or toe even

though amputation of the part would not warrant a

compensable evaluation.

(See § 4.68 of this part on the amputation rule.)

7805 Scars, other; Rate on limitation of function of

affected part.

7806 Dermatitis or eczema.

More than 40 percent of the entire body or more than 40 60

percent of exposed areas affected, or; constant or near-

constant systemic therapy such as corticosteroids or

other immunosuppressive drugs required during the past

12-month period

20 to 40 percent of the entire body or 20 to 40 percent 30

of exposed areas affected, or; systemic therapy such as

corticosteroids or other immunosuppressive drugs required

for a total duration of six weeks or more, but not

constantly, during the past 12-month period

At least 5 percent, but less than 20 percent, of the 10

entire body, or at least 5 percent, but less than 20

percent, of exposed areas affected, or; intermittent

systemic therapy such as corticosteroids or other

immunosuppressive drugs required for a total duration of

less than six weeks during the past 12-month period

Less than 5 percent of the entire body or less than 5 0

percent of exposed areas affected, and; no more than

topical therapy required during the past 12-month period

Or rate as disfigurement of the head, face, or neck (DC

7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),

depending upon the predominant disability.

7807 American (New World) leishmaniasis (mucocutaneous,

espundia):

Rate as disfigurement of the head, face, or neck (DC

7800), scars (DC's 7801, 7802, 7803, 7804, or 7805), or

dermatitis (DC 7806), depending upon the predominant

disability

Note: Evaluate non-cutaneous (visceral) leishmaniasis

under DC 6301 (visceral leishmaniasis).

7808 Old World leishmaniasis (cutaneous, Oriental sore):

Rate as disfigurement of the head, face, or neck (DC

7800), scars (DC's, 7801, 7802, 7803, 7804, or 7805), or

dermatitis (DC 7806), depending upon the predominant

disabililty

Note: Evaluate non-cutaneous (visceral) leishmaniasis

under DC 6301 (visceral leishmaniasis).

7809 Discoid lupus erythematosus or subacute cutaneous

lupus erythematosus:

Rate as disfigurement of the head, face, or neck (DC

7800), scars (DC's 7801, 7802, 7803, 7804, or 7805), or

dermatitis (DC 7806), depending upon the predominant

disability. Do not combine with ratings under DC 6350

7811 Tuberculosis luposa (lupus vulgaris), active or

inactive:

Rate under §§ 4.88c or 4.89, whichever is appropriate

7813 Dermatophytosis (ringworm: of body, tinea corporis;

of head, tinea capitis; of feet, tinea pedis; of beard

area, tinea barbae; of nails, tinea unguium; of inguinal

area (jock itch), tinea cruris):

Rate as disfigurement of the head, face, or neck (DC

7800), scars (DC's 7801, 7802, 7803, 7804, or 7805), or

dermatitis (DC 7806), depending upon the predominant

disability

7815 Bullous disorders (including pemphigus vulgaris,

pemphigus foliaceous, bullous pemphigoid, dermatitis

herpetiformis, epidermolysis bullosa acquisita, benign

chronic familial pemphigus (Hailey-Hailey), and porphyria

cutanea tarda):

More than 40 percent of the entire body or more than 40 60

percent of exposed areas affected, or; constant or near-

constant systemic therapy such as corticosteroids or

other immunosuppressive drugs required during the past

12-month period

20 to 40 percent of the entire body or 20 to 40 percent 30

of exposed areas affected, or; systemic therapy such as

corticosteroids or other immunosuppressive drugs required

for a total duration of six weeks or more, but not

constantly, during the past 12-month period

At least 5 percent, but less than 20 percent, of the 10

entire body, or at least 5 percent, but less than 20

percent, of exposed areas affected, or; intermittent

systemic therapy such as corticosteroids or other

immunosuppressive drugs required for a total duration of

less than six weeks during the past 12-month period

Less than 5 percent of the entire body or exposed areas 0

affected, and; no more than topical therapy required

during the past 12-month period

Or rate as disfigurement of the head, face, or neck (DC

7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),

depending upon the predominant disability.

7816 Psoriasis:

More than 40 percent of the entire body or more than 40 60

percent of exposed areas affected, or; constant or near-

constant systemic therapy such as corticosteroids or

other immunosuppressive drugs required during the past

12-month period

20 to 40 percent of the entire body or 20 to 40 percent 30

of exposed areas affected, or; systemic therapy such as

corticosteroids or other immunosuppressive drugs required

for a total duration of six weeks or more, but not

constantly, during the past 12-month period

At least 5 percent, but less than 20 percent, of the 10

entire body, or at least 5 percent, but less than 20

percent, of exposed areas affected, or; intermittent

systemic therapy such as corticosteroids or other

immunosuppressive drugs required for a total duration of

less than six weeks during the past 12-month period

Less than 5 percent of the entire body or exposed areas 0

affected, and; no more than topical therapy required

during the past 12-month period

Or rate as disfigurement of the head, face, or neck (DC

7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),

depending upon the predominant disability.

7817 Exfoliative dermatitis (erythroderma):

Generalized involvement of the skin, plus systemic 100

manifestations (such as fever, weight loss, and

hypoproteinemia), and; constant or near-constant systemic

therapy such as therapeutic doses of corticosteroids,

immunosuppressive retinoids, PUVA (psoralen with long-

wave ultraviolet-A light) or UVB (ultraviolet-B light)

treatments, or electron beam therapy required during the

past 12-month period

Generalized involvement of the skin without systemic 60

manifestations, and; constant or near-constant systemic

therapy such as therapeutic doses of corticosteroids,

immunosuppressive retinoids, PUVA (psoralen with long-

wave ultraviolet-A light) or UVB (ultraviolet-B light)

treatments, or electron beam therapy required during the

past 12-month period

Any extent of involvement of the skin, and; systemic 30

therapy such as therapeutic doses of corticosteroids,

immunosuppressive retinoids, PUVA (psoralen with long-

wave ultraviolet-A light) or UVB (ultraviolet-B light)

treatments, or electron beam therapy required for a total

duration of six weeks or more, but not constantly, during

the past 12-month period

Any extent of involvement of the skin, and; systemic 10

therapy such as therapeutic doses of corticosteroids,

immunosuppressive retinoids, PUVA (psoralen with long-

wave ultraviolet-A light) or UVB (ultraviolet-B light)

treatments, or electron beam therapy required for a total

duration of less than six weeks during the past 12-month

period

Any extent of involvement of the skin, and; no more than 0

topical therapy required during the past 12-month period

7818 Malignant skin neoplasms (other than malignant

melanoma):

Rate as disfigurement of the head, face, or neck (DC

7800), scars (DC's 7801, 7802, 7803, 7804, or 7805), or

impairment of function

Note: If a skin malignancy requires therapy that is

comparable to that used for systemic malignancies, i.e.,

systemic chemotherapy, X-ray therapy more extensive than

to the skin, or surgery more extensive than wide local

excision, a 100-percent evaluation will be assigned from

the date of onset of treatment, and will continue, with a

mandatory VA examination six months following the

completion of such antineoplastic treatment, and any

change in evaluation based upon that or any subsequent

examination will be subject to the provisions of §

3.105(e) of this chapter. If there has been no

local recurrence or metastasis, evaluation will then be

made on residuals. If treatment is confined to the skin,

the provisions for a 100-percent evaluation do not apply.

7819 Benign skin neoplasms:

Rate as disfigurement of the head, face, or neck (DC

7800), scars (DC's 7801, 7802, 7803, 7804, or 7805), or

impairment of function

7820 Infections of the skin not listed elsewhere

(including bacterial, fungal, viral, treponemal and

parasitic diseases):

Rate as disfigurement of the head, face, or neck (DC

7800), scars (DC's 7801, 7802, 7803, 7804, or 7805), or

dermatitis (DC 7806), depending upon the predominant

disability

7821 Cutaneous manifestations of collagen-vascular

diseases not listed elsewhere (including scleroderma,

calcinosis cutis, and dermatomyositis):

More than 40 percent of the entire body or more than 40 60

percent of exposed areas affected, or; constant or near-

constant systemic therapy such as corticosteroids or

other immunosuppressive drugs required during the past

12-month period

20 to 40 percent of the entire body or 20 to 40 percent 30

of exposed areas affected, or; systemic therapy such as

corticosteroids or other immunosuppressive drugs required

for a total duration of six weeks or more, but not

constantly, during the past 12-month period

At least 5 percent, but less than 20 percent, of the 10

entire body, or at least 5 percent, but less than 20

percent, of exposed areas affected, or; intermittent

systemic therapy such as corticosteroids or other

immunosuppressive drugs required for a total duration of

less than six weeks during the past 12-month period

Less than 5 percent of the entire body or exposed areas 0

affected, and; no more than topical therapy required

during the past 12-month period

Or rate as disfigurement of the head, face, or neck (DC

7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),

depending upon the predominant disability.

7822 Papulosquamous disorders not listed elsewhere

(including lichen planus, large or small plaque

parapsoriasis, pityriasis lichenoides et varioliformis

acuta (PLEVA), lymphomatoid papulosus, and pityriasis

rubra pilaris (PRP)):

More than 40 percent of the entire body or more than 40 60

percent of exposed areas affected, and; constant or near-

constant systemic medications or intensive light therapy

required during the past 12-month period

light therapy required for a total duration of

six weeks or more, but not constantly, during the past

12-month period

or intensive light therapy required for a total duration

of less than six weeks during the past 12-month period

Less than 5 percent of the entire body or exposed areas 0

affected, and; no more than topical therapy required

during the past 12-month period

Or rate as disfigurement of the head, face, or neck (DC

7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),

depending upon the predominant disability.

7823 Vitiligo:

With exposed areas affected 10

With no exposed areas affected 0

7824 Diseases of keratinization (including icthyoses,

Darier's disease, and palmoplantar keratoderma):

With either generalized cutaneous involvement or systemic 60

manifestations, and; constant or near-constant systemic

medication, such as immunosuppressive retinoids, required

during the past 12-month period

With either generalized cutaneous involvement or systemic 30

manifestations, and; intermittent systemic medication,

such as immunosuppressive retinoids, required for a total

duration of six weeks or more, but not constantly, during

the past 12-month period

With localized or episodic cutaneous involvement and 10

intermittent systemic medication, such as

immunosuppressive retinoids, required for a total

duration of less than six weeks during the past 12-month

period

No more than topical therapy required during the past 12- 0

month period

7825 Urticaria:

Recurrent debilitating episodes occurring at least four 60

times during the past 12-month period despite continuous

immunosuppressive therapy

Recurrent debilitating episodes occurring at least four 30

times during the past 12-month period, and; requiring

intermittent systemic immunosuppressive therapy for

control

Recurrent episodes occurring at least four times during 10

the past 12-month period, and; responding to treatment

with antihistamines or sympathomimetics

7826 Vasculitis, primary cutaneous:

Recurrent debilitating episodes occurring at least four 60

times during the past 12-month period despite continuous

immunosuppressive therapy

Recurrent debilitating episodes occurring at least four 30

times during the past 12-month period, and; requiring

intermittent systemic immunosuppressive therapy for

control

Recurrent episodes occurring one to three times during 10

the past 12-month period, and; requiring intermittent

systemic immunosuppressive therapy for control

Or rate as disfigurement of the head, face, or neck (DC

7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),

depending upon the predominant disability.

7827 Erythema multiforme; Toxic epidermal necrolysis:

Recurrent debilitating episodes occurring at least four 60

times during the past 12-month period despite ongoing

immunosuppressive therapy

Recurrent episodes occurring at least four times during 30

the past 12-month period, and; requiring intermittent

systemic immunosuppressive therapy

Recurrent episodes occurring during the past 12-month 10

period that respond to treatment with antihistamines or

sympathomimetics, or; one to three episodes occurring

during the past 12-month period requiring intermittent

systemic immunosuppressive therapy

Or rate as disfigurement of the head, face, or neck (DC

7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),

depending upon the predominant disability.

7828 Acne:

Deep acne (deep inflamed nodules and pus-filled cysts) 30

affecting 40 percent or more of the face and neck

Deep acne (deep inflamed nodules and pus-filled cysts) 10

affecting less than 40 percent of the face and neck, or;

deep acne other than on the face and neck

Superficial acne (comedones, papules, pustules, 0

superficial cysts) of any extent

Or rate as disfigurement of the head, face, or neck (DC

7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),

depending upon the predominant disability.

7829 Chloracne:

Deep acne (deep inflamed nodules and pus-filled cysts) 30

affecting 40 percent or more of the face and neck

Deep acne (deep inflamed nodules and pus-filled cysts) 10

affecting less than 40 percent of the face and neck, or;

deep acne other than on the face and neck

Superficial acne (comedones, papules, pustules, 0

superficial cysts) of any extent

Or rate as disfigurement of the head, face, or neck (DC

7800) or scars (DC's 7801, 7802, 7803, 7804, or 7805),

depending upon the predominant disability.

7830 Scarring alopecia:

Affecting more than 40 percent of the scalp 20

Affecting 20 to 40 percent of the scalp 10

Affecting less than 20 percent of the scalp 0

7831 Alopecia areata:

With loss of all body hair 10

With loss of hair limited to scalp and face 0

7832 Hyperhidrosis:

Unable to handle paper or tools because of moisture, and 30

unresponsive to therapy

Able to handle paper or tools after therapy 0

7833 Malignant melanoma:

Rate as scars (DC's 7801, 7802, 7803, 7804, or 7805),

disfigurement of the head, face, or neck (DC 7800), or

impairment of function (under the appropriate body system)

Note: If a skin malignancy requires therapy that is

comparable to that used for systemic malignancies, i.e.,

systemic chemotherapy, X-ray therapy more extensive than

to the skin, or surgery more extensive than wide local

excision, a 100-percent evaluation will be assigned from

the date of onset of treatment, and will continue, with a

mandatory VA examination six months following the

completion of such antineoplastic treatment, and any

change in evaluation based upon that or any subsequent

examination will be subject to the provisions of

§

3.105(e). If there has been no local recurrence or

metastasis, evaluation will then be made on residuals. If

treatment is confined to the skin, the provisions

for a 100-percent evaluation do not apply.

Source

[29 FR 6718, May 22, 1964, as amended at 34 FR 5063, Mar. 11, 1969; 40 FR 42540, Sept. 15, 1975; 43 FR 45262, Oct. 2, 1978; 67 FR 49590, 49596, July 31, 2002, as corrected at 67 FR 58448, Sept. 16, 2002]

Alex